Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RDW was higher in subjects with palpable splenomegal...
Alternative Titles
Full title
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3085113491
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3085113491
Other Identifiers
ISSN
0939-5555,1432-0584
E-ISSN
1432-0584
DOI
10.1007/s00277-024-05801-0
